Focused On-demand Library for Interleukin-4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P05112

UPID:

IL4_HUMAN

Alternative names:

B-cell stimulatory factor 1; Binetrakin; Lymphocyte stimulatory factor 1; Pitrakinra

Alternative UPACC:

P05112; Q14630; Q6NZ77

Background:

Interleukin-4 (IL-4), encoded by the P05112 gene, is a pivotal cytokine secreted by mast cells, T-cells, eosinophils, and basophils. It plays a crucial role in regulating antibody production, hematopoiesis, inflammation, and T-cell responses. IL-4 induces class II MHC molecules expression on B-cells, enhances IgE and IgG1 secretion, and regulates CD23 expression on lymphocytes and monocytes. It also promotes IL31RA expression in macrophages, stimulates autophagy in dendritic cells, and supports brain functions like memory and learning.

Therapeutic significance:

Given its involvement in ischemic stroke, a condition leading to brain tissue death and loss of function due to vascular occlusion, IL-4's understanding could pave the way for innovative therapeutic strategies targeting this complex disease with multiple genetic and environmental factors.